Skip to main content

Table 2 Patient characteristics of studies proposed for inclusion in meta-analysis

From: Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design

Trial (drug) by Year n Mean age Male Mean EF Diabetes On ACEi/ARB Mean SBP (mmHg) Mean HR (bpm)
MDC (metoprolol) 1993 383 49 72% 22% n/s 79% 118 91
CIBIS (bisoprolol) 1994 641 60 83% 25% n/s 90% 126 83
US-HF (carvedilol) 1996 1,094 58 77% 23% 29% 95% 116 84
ANZ (carvedilol) 1997 415 67 80% 29% 19% 85% n/s n/s
CIBIS II (bisoprolol) 1999 2,647 61 80% 28% 12% 96% 130 80
MERIT-HF (metoprolol XL) 1999 3,991 64 78% 28% 25% 96% 130 83
COPERNICUS (carvedilol) 2001 2,289 63 80% 20% 26% 97% 123 83
CAPRICORN (carvedilol) 2001 1,959 63 74% 33% 22% 98% 121 77
BEST (bucindolol) 2001 2,708 60 78% 23% 36% 98% 117 82
CHRISTMAS (carvedilol) 2003 (375)* 63 90% 29% 22% 87% 126 78
SENIORS (nebivolol) 2005 2,128 76 63% 36% 26% 89% 139 79
TOTAL / WEIGHTED MEAN 18,630 63 77% 27% 23% 95% 126 81
  1. ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; EF, ejection fraction; HR, heart rate; n/s, not specified; SBP, systolic blood pressure.
  2. * Characteristics reported are for the 305 participants with available radionuclide ventriculograms, as per the original publication.